Coherus Oncology Inc (CHRS)

R&D Expenses

$98.47M

TTM · Period ending: · USD

CHRS logo

CHRS R&D Expenses

Latest reported$98.47M
CHRS TTM R&D Expenses ($31.78M → $98.47M)
High-resolution chart · PNG

CHRS r&d expenses history

Trailing twelve months (TTM) · USD. Each value covers four complete reported quarters.

Coherus Oncology Inc R&D Expenses — Trailing twelve months (TTM) (USD)
Period endingR&D Expenses (USD)
98,468,000
102,316,000
104,964,000
96,121,000
91,511,000
86,989,000
92,103,000
97,236,000
101,207,000
103,706,000
109,436,000
112,090,000
132,251,000
150,595,000
199,358,000
221,098,000
229,375,000
242,530,000
363,105,000
356,971,000
341,737,000
313,144,000
142,759,000
133,079,000
115,796,000
108,506,000
94,188,000
85,902,000
95,937,000
103,573,000
110,239,000
115,065,000
126,088,000
134,069,000
162,389,000
189,911,000
211,858,000
242,902,000
254,440,000
246,863,000
250,508,000
241,908,000
213,062,000
188,496,000
138,774,000
100,755,000
78,224,000
60,579,000
47,017,000
37,059,000
31,779,000
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.